Activity and research directory projects

The directory lists antimicrobial resistance (AMR) activities and research and displays whether they are in progress or completed. Use the filters and search to help refine your query.

4 activities or research projects found
  • 1 July 2019
    This project aims to employ novel approaches to discover new-generation polymyxin antibiotics targeting the deadly Gram-negative ‘superbugs’. Novel lead molecules have been licensed to Qpex Biopharma (US) for IND-enabling evaluations with a Phase-I study aimed at 2020.
    Monash University and I (Jian Li, Professor, PhD) am the principal investigator. My project is currently funded by the American National Institutes of Health (NIH). More information at https://www.monash.edu/discovery-institute/news-and-events/news/2019-articles/us-biopharmaceutical-company-licenses-monash-university-superbug-drug-discovery
  • 27 June 2019
    We are working with clinicians in the Center for Innovative Phage Applications and Therapeutics at the University of California in San Diego. Phage therapy is frontier medicine, and has FDA approval for use in hospitals in the USA. Isolating clinically-effective "cocktails" is a challenge that can only be met by collaboration between research scientists trained in phage biology (Monash) and clinicians with experience in clinical deployment (UCSD).
    Monash University.
    University of California in San Diego.
  • 27 June 2019
    We have engaged with partners in Wenzhou, China to analyze the recent rise in AMR in their hospitals. In 2019, we opened the Monash BDI-WMU Alliance in Clinical and Experimental Biomedicine on the campus of Wenzhou Medical University. Initial assessments of one species of bacteria reveals that 15 years ago, less than ten patients per annum were infected, all of which responded to off the shelf antibiotics. Last year, 990 patients had infections s, with ~1 in 3 being AMR.
    Biomedicine Discovery Institute, Monash University, Australia.
    Wenzhou Medical University, China.
  • 24 April 2018
    The National Centre for Antimicrobial Stewardship (NCAS) is a health services research program that aims to generate evidence on antimicrobial use and stewardship, influence national policy to promote judicious use of antimicrobials across human and animal health, and improve knowledge and build workforce capacity among all stakeholders. NCAS’ research streams include: tertiary hospitals, rural and regional hospitals, aged care homes, general practice, and veterinary and agricultural medicine.
    National Centre for Antimicrobial Stewardship; University of Melbourne; Royal Melbourne Hospital; Peter Doherty Institute for Infection and Immunity; Monash University.